ECO’s recent Capital Markets Day lifted the lid for the first time on its pipeline of new products in development. At a cost of £10m pa, it has been developing a range of complementary vaccines and therapeutics, from which it can leverage its strong brand and established routes to market in larger and higher margin segments of the market. This has the potential to transform the investment case for the group, significantly increasing and extending the growth runway, improving margins and returns ....
